Physician profile
Mingran Yu
NPI 1932846102
$1,589.65
in general payments reported to CMS, 2019-2025
13 companies · $1,189 in 2025
The $1,189 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $230 · 2024: $171 · 2025: $1,189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,505 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,504.66 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $313.76 | 2023-2025 | Farxiga, Airsupra, Lokelma |
| Abbott Laboratories | $271.94 | 2025 | Cardiomems |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $228.96 | 2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $189.78 | 2024-2025 | Camzyos, Eliquis |
| Novo Nordisk INC | $124.00 | 2023 | Wegovy |
| Novartis Pharmaceuticals Corporation | $116.66 | 2025 | |
| Abiomed | $112.49 | 2025 | |
| Scpharmaceuticals INC. | $62.48 | 2025 | |
| Impulse Dynamics (USA) INC. | $58.39 | 2025 | Optimizer |
| Pfizer INC. | $42.87 | 2025 | |
| Mannkind Corporation | $27.97 | 2025 | |
| Lantheus Medical Imaging, INC. | $22.26 | 2025 | |
| Janssen Pharmaceuticals, INC | $18.09 | 2024 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mingran Yu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.